Literature DB >> 15009110

Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin.

L Tang1, L Cao, J P Sundberg, H Lui, J Shapiro.   

Abstract

Anthralin is a widely used topical anti-psoriatic drug that may have an immunomodulating effect on alopecia areata (AA) as it does in psoriasis. The aims of the present study were to investigate the effects of anthralin on hair growth in balding C3H/HeJ mice affected by an AA-like disease and to study the underlying mechanisms. Affected C3H/HeJ mice were treated daily for 10 weeks on half of the dorsal skin with 0.2% anthralin and the contra-lateral side was treated with the vehicle ointment. The percentage of surface hair coverage and hair density was graded weekly for both sides and hair growth indices were calculated using these two variables. Hair regrowth was observed in 9/14 mice on the treated sides. Four mice displayed near complete replacement of normal density and length hairs. All the vehicle-treated sides showed either no change or continued hair loss. An RNase protection assay (RPA) showed that expression of tumor necrosis factor-alpha (TNF-alpha) and -beta were inhibited by anthralin upon successful treatment. It appears that anthralin may be an effective therapy for C3H/HeJ mice with AA and certain cytokines may be involved in the therapeutic effects of anthralin on restoring hair regrowth in AA-affected C3H/HeJ mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009110     DOI: 10.1111/j.0906-6705.2004.00098.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

Review 1.  Lymphocytes, neuropeptides, and genes involved in alopecia areata.

Authors:  Amos Gilhar; Ralf Paus; Richard S Kalish
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results.

Authors:  Jing Sun; Kathleen A Silva; Kevin J McElwee; Lloyd E King; John P Sundberg
Journal:  Exp Dermatol       Date:  2008-10       Impact factor: 3.960

3.  Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study.

Authors:  Rattapon Thuangtong; Saroj Suvansuthi; Pitchaya Maneeprasopchoke; Thanisorn Sukakul; Rattiya Techakajornkeart; Pichanee Chaweekulrat; Supisara Wongdama; Daranporn Triwongwaranat
Journal:  Int J Trichology       Date:  2022-05-24

4.  Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model.

Authors:  Motonobu Nakamura; Jun-ichiro Jo; Yasuhiko Tabata; Osamu Ishikawa
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

Review 5.  New and Emerging Therapies for Alopecia Areata.

Authors:  Aunna Pourang; Natasha Atanaskova Mesinkovska
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

6.  Endogenous retinoids in the pathogenesis of alopecia areata.

Authors:  F Jason Duncan; Kathleen A Silva; Charles J Johnson; Benjamin L King; Jin P Szatkiewicz; Sonya P Kamdar; David E Ong; Joseph L Napoli; Jinshan Wang; Lloyd E King; David A Whiting; Kevin J McElwee; John P Sundberg; Helen B Everts
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

7.  Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.

Authors:  Jin Wang; Silvia Gines; Marcy E MacDonald; James F Gusella
Journal:  BMC Neurosci       Date:  2005-01-13       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.